National projects
Range:
Introducing PROTAKs: Evaluation of TAK1 chimeric degraders as a treatment option for rheumatoid arthritis
One of the most common autoimmune diseases is rheumatoid arthritis (RA), a chronic condition in which the immune system attacks the body's own joints, leading to inflammation, pain, swelling, and progressive joint damage. This disease can cause joint deformities and limited mobility, significantly affecting the quality of patients’ life. Treating and alleviati...
Development of Carbamoyl Fluorides as Warheads to Target Orphan Enzymes
About 10% of approved drugs form a covalent bond with their macromolecular target. Covalent drugs, previously neglected due to safety concerns, have recently taken centre stage in drug discovery programs as they pose certain advantages over non-covalent drugs, namely higher potency, longer residence time, decoupling of pharmacokinetics and pharmacodynamics, and incr...
Preclinical development of mitochondrial chaperone TRAP1 inhibitors as anticancer agents
Despite significant improvements in treatment and survival rates, cancer remains one of the leading causes of death worldwide. Therefore, there is an urgent need for new drugs that act on novel targets to improve treatment outcomes, particularly against some aggressive cancers for which there are no standard therapies. The MitoTRAP (Preclinical development of mitoch...